Founder and Chief Scientific Officer
Dr. Danilkovitch is the Founder and Chief Scientific Officer of Britecyte. She founded the biotechnology company in 2020. Her main area of scientific expertise is regenerative medicine including stem cells. From 2003 to 2019, Dr. Danilkovitch worked at Osiris Therapeutics, occupying several leadership positions including Chief Scientific Officer. She has a proven record of successful product development from scientific ideas to market launch. The list includes the world’s first approved stem cell drug Prochymal® for graft-versus-host disease and regenerative medicine products such as BIO4™ for bone repair, Cartiform® for cartilage repair, Grafix® for acute and chronic wounds, and Stravix™ for soft tissue repair. Her latest invention was Prestige LyotechnologySM, a tissue preservation method allowing living tissue storage at room temperature. The development of unique products and technologies by Dr. Danilkovitch led to Osiris’ acquisition by Smith+Nephew in 2019. After the acquisition she served as Vice President of Biologics and Regenerative Medicine R&D at Smith+Nephew (2019-2020).
Dr. Danilkovitch has more than 30 years of experience in Academia, US Government, and Industry combined. She is an active member of several professional societies and a reviewer for many peer-reviewed journals including Stem Cells, Allergy & Inflammation, and Advances in Wound Care. Dr. Danilkovitch also has an extensive list of awards (14), publications (60), and patents (55). Prior to 2003, she conducted research at the National Cancer Institute, the Max Planck Institute of Biochemistry, the Etvos Lorand University, and at the Moscow State University. She earned a PhD degree in Cell Biology from Moscow State University. She also has a RN degree in Pediatrics from the Moscow Regional School of Nursing and a MS degree in microbiology and immunology from the Moscow State University.